«Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?». Journal of Gastroenterology34 (4): 435–40. August 1999. doi:10.1007/s005350050292. PMID10452673.
«Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer». The Journal of International Medical Research31 (6): 469–74. 2003. doi:10.1177/147323000303100601. PMID14708410.
«Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease». Alimentary Pharmacology & Therapeutics21 (Suppl 2): 10–8. June 2005. doi:10.1111/j.1365-2036.2005.02468.x. PMID15943841.
«Effects of famotidine on gastric pH and residual volume in pediatric surgery». Acta Anaesthesiologica Scandinavica35 (5): 457–60. July 1991. doi:10.1111/j.1399-6576.1991.tb03328.x. PMID1887750.
«NADAC as of 2019-02-27». Centers for Medicare and Medicaid Services (στα Αγγλικά). Αρχειοθετήθηκε από το πρωτότυπο στις 6 Μαρτίου 2019. Ανακτήθηκε στις 3 Μαρτίου 2019.
nih.gov
ncbi.nlm.nih.gov
«[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication]». Nihon Rinsho. Japanese Journal of Clinical Medicine57 (1): 153–6. January 1999. PMID10036954.
«Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?». Journal of Gastroenterology34 (4): 435–40. August 1999. doi:10.1007/s005350050292. PMID10452673.
«Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer». The Journal of International Medical Research31 (6): 469–74. 2003. doi:10.1177/147323000303100601. PMID14708410.
«[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer]». Terapevticheskii Arkhiv76 (2): 18–22. 2004. PMID15106408.
«Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease». Alimentary Pharmacology & Therapeutics21 (Suppl 2): 10–8. June 2005. doi:10.1111/j.1365-2036.2005.02468.x. PMID15943841.
«Effects of famotidine on gastric pH and residual volume in pediatric surgery». Acta Anaesthesiologica Scandinavica35 (5): 457–60. July 1991. doi:10.1111/j.1399-6576.1991.tb03328.x. PMID1887750.
«NADAC as of 2019-02-27». Centers for Medicare and Medicaid Services (στα Αγγλικά). Αρχειοθετήθηκε από το πρωτότυπο στις 6 Μαρτίου 2019. Ανακτήθηκε στις 3 Μαρτίου 2019.